BioSpace News Archive

Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) is pleased to announce that the clinical trial results, for novel anti-aging compound TFC-1326, have exceeded even high expectations on key criteria.

Strata Oncology, Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, announced the launch of Strata Select™, a first-of-its-kind molecular profiling test for patients with advanced cancer.

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, announces publication of an article in the peer-reviewed Journal of Neuroinflammation supporting the potential of ASC specks as a therapeutic target for Parkinson’s disease.

Neurelis, Inc. will present four posters from the completed long-term, open-label, repeat-dose safety study of VALTOCO for the treatment of episodes of frequent seizure activity (i.e., seizure clusters) in patients with epilepsy ages 6 to 65 years.

Endonovo Therapeutics, Inc. (OTCQB: ENDV), a leading developer of medical technologies, today announced it is moving forward in its clinical development in the field of Traumatic Brain Injury (TBI) treatment.

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced the opening of a clinical trial to study its investigational Tri-Ad5 vaccine combination (Adenovirus 5 CEA/MUC1/brachyury) together with its IL-15 superagonist N-803, an immune-enhancer, for people with a hereditary condition known as Lynch syndrome.

Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its first quarter 2023 results on Tuesday, May 9, 2023.

Qosina, a global supplier of OEM single-use components to the medical and biopharmaceutical industries, is pleased to introduce CPC’s new AseptiQuik® W Series connectors to its extensive line of aseptic genderless connectors.

Indivior PLC (LSE: INDV) today announced that it will participate in the following investor event.

The Celiac Disease Foundation, a world leader in patient advocacy, and Takeda Development Center Americas, a global biopharmaceutical leader, are proud to announce the Celiac Disease Foundation–Takeda Early Career Research Award; an award designed to attract promising researchers to the study of celiac disease.